Cyclo (RLsKDK)

• Description:

  Cyclo (RLsKDK) (BK-1361) is a specific inhibitor of metalloproteinase ADAM8 with an IC50 value of 182 nM. cyclo (RLsKDK) has potential applications in inflammatory diseases and cancer[1].

• Product Name Alternative:

  BK-1361

• UNSPSC:

  12352209

• Target:

  MMP

• Type:

  Peptides

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cyclo-rlskdk.html

• Purity:

  98.85

• Solubility:

  DMSO : 3.33 mg/mL (ultrasonic)

• Smiles:

  N=C (N) NCCC[C@@H] (C (N[C@H] (C (N[C@@H] (C (N[C@H]1CCCCN) =O) CO) =O) CC (C) C) =O) NC ([C@@H] (NC ([C@@H] (NC1=O) CC (O) =O) =O) CCCCN) =O

• Molecular Formula:

  C31H57N11O9

• Molecular Weight:

  727.85

• References & Citations:

  [1]Yim V, et al. Synthesis and biological evaluation of analogues of the potent ADAM8 inhibitor cyclo (RLsKDK) for the treatment of inflammatory diseases and cancer metastasis. Bioorg Med Chem. 2016 Sep 15;24 (18) :4032-4037. |[2]Schlomann U, et al. ADAM8 as a drug target in pancreatic cancer. Nat Commun. 2015 Jan 28;6:6175.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Scientific Category:

  Peptides

• Clinical Information:

  No Development Reported

• CAS Number:

  1975145-82-4